## SENTARA COMMUNITY PLAN (MEDICAID)

## PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request</u>. All other information may be filled in by office staff; <u>fax to 1-800-750-9692</u>. No additional phone calls will be necessary if all information (<u>including phone and fax #s</u>) on this form is correct. <u>If the information provided is not complete, correct, or legible, the authorization process can be delayed.</u>

**Drug Requested:** Lodoco® (colchicine)

MEMBER & PRESCRIBER INFORMATION:	Authorization may be delayed if incomplete.
Member Name:	
Member Sentara #:	Date of Birth:
Prescriber Name:	
Prescriber Signature:	Date:
Office Contact Name:	
Phone Number:	
DEA OR NPI #:	
DRUG INFORMATION: Authorization may be dela	yed if incomplete.
Drug Form/Strength:	
Dosing Schedule:	
Diagnosis:	ICD Code, if applicable:
Weight:	Date:
Quantity Limit: 1 tablet per day	
CLINICAL CRITERIA: Check below all that apply. support each line checked, all documentation, including lab provided or request may be denied.	
<b>Initial Authorization</b> : 12 months	
☐ Member is 35 years of age or older	
Requested medication will be used to reduce the ri revascularization, and cardiovascular death in adult with multiple risk factors for cardiovascular disease	

(Continued on next page)

Prescribed by or in consultation with a provider specializing in heart disease (i.e., cardiology, lipidology)

	<ul> <li>Member has Atherosclerotic Cardiovascular Disease (ASCVD) confirmed by at least ONE of the following:</li> <li>□ History of myocardial infarction or a history of an acute coronary syndrome</li> <li>□ Stable or unstable angina</li> <li>□ History of Stroke</li> <li>□ History of Transient ischemic attack</li> <li>□ Peripheral arterial disease presumed to be of atherosclerotic origin</li> <li>□ Member has undergone coronary or other arterial revascularization procedure in the past (e.g., coronary artery bypass graft surgery, percutaneous coronary intervention, angioplasty, and coronary stent procedures</li> </ul>	
	<ul> <li>Member must meet ONE of the following (verified by chart notes and/or pharmacy paid claims):</li> <li>Member will continue background therapy with maximally tolerated statin therapy (e.g., atorvastatin, rosuvastatin, simvastatin)</li> <li>If member is statin intolerant, member will continue background therapy with maximally tolerated non-statin lipid-lowering agents (e.g., ezetimibe, Repatha, fenofibric acid) unless contraindicated or not tolerated</li> </ul>	
	Requested medication is being added onto other background regimens of other ASCVD disease medications according to the prescriber. Note: Examples of medications recommended in guideline-directed therapy for patients with atherosclerotic disease can include aspirin, antiplatelet agents (e.g., clopidogrel, Brilinta [ticagrelor tablets]), anticoagulants, beta blockers, angiotensin-converting enzyme inhibitors, and/or angiotensin receptor blockers.	
	Member's blood pressure is controlled and stable on current antihypertensive therapy  Provider attests member does <u>NOT</u> have any of the following comorbidities:  Renal failure (i.e., CrCl < 15 mL/min)  Severe liver impairment  Pre-existing blood dyscrasias  Concurrent use of strong CYP3A4 or P-gp inhibitors	
ıppo	uthorization: 12 months. Check below all that apply. All criteria must be met for approval. To ort each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be ded or request may be denied	
<u> </u>	Member continues to meet all initial authorization criteria  Provider must submit documentation indicating improvement in member's condition and attests member continues to benefit from therapy with requested medication	

\*\*Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. \*\*

\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes. \*

\*Approved by Pharmacy and Therapeutics Committee: 11/16/2023 REVISED/UPDATED: 12/20/2023